Nuclear medicine and physics
Composition:
Chair: Lise Borgwardt (Denmark) - Lise.Borgwardt@regionh.dk
Vice chair: Bart de Keizer (The Netherlands) - b.dekeizer@umcutrecht.nl
Members:
Tereza Kracmerova (Czech Republic)
Katerina Taborska (Czech Republic)
Kim Francis (Denmark)
Anne Sophie Defachelles (France)
Aurore Oudoux (France)
Helene Gauthier (France)
Holger Amthauer (Germany)
Julian Rogash (Germany)
Vassiliki Lyra (Greece)
Zvi Bar-Sever (Israel)
Alice Benigna (Italy)
Alice Lorenzoni (Italy)
Alice Monaci (Italy)
Anna Lisa Martini (Italy)
Arnoldo Piccardo (Italy)
Bartolomeo Cassano (Italy)
Carlo Chiesa (Italy)
Catia Olianti (Italy)
Gianluca Bottoni (Italy)
Giulia Anna Follachio (Italy)
Maria Carmen Garganese (Italy)
Maria Felicia Villani (Italy)
Maria Rita Castellani (Italy)
Michela Allocca (Italy)
Milena Pizzoferro (Italy)
Paola Saletti (Italy)
Vittorio Cannatà (Italy)
Jelena Rascon (Lithuania)
Renata Komiagiene (Lithuania)
Lars Mikalsen (Norway)
Anna Sliwinska (Poland)
Teresa Ferreira (Portugal)
Irene Torres (Spain)
Isabel Roca (Spain)
Julia Balaguer (Spain)
Pablo Minguez (Spain)
Raquel Sanchez (Spain)
Stefan Prado (Spain)
Laure Michaud (Switzerland)
Nedim Gulaldi (Turkey)
Glenn Flux (United Kingdom)
Hugh Wallace (United Kingdom)
Karolina Switaj (United Kingdom)
Matthey Aldrige (United Kingdom)
Michael Bradnam (United Kingdom)
Sarah Kelly (United Kingdom)
Simon Wan (United Kingdom)
Aims
To harmonise and advance nuclear medicine and physics in children with neuroblastoma by improving access to tracers, standardising imaging, supporting research and development of radionuclide treatment and integrating innovative techniques into SIOPEN trials to benefit children with neuroblastoma worldwide.
Key Achievements
Position paper on imaging of HR-NB and NucMed/Physics work group with Radiology Committee (submitted to Pediatric Blood and Cancer)
Survey sent out to national delegates concerning imaging protocols and availability of PET-scanner and cyclotrons, and different tracers in sites participating in the HR2 trial.
Objectives
For the next year:
Collaborate with industry to make MFBG available in as many sites as possible worldwide.
Promote the introduction of PET tracers in new study protocols for neuroblastoma trials.
Analyse the survey among participating sites in HR2 trial on imaging facilities and possibilities in sites participating in neuroblastoma trials. (goal to get an overview on current practices, use of PET tracers and feasibility of sites to switch from [123I]mIBG to MFBG and other PET tracers)
Write a manuscript/recommendation on the scoring of (MFBG) PET scans in neuroblastoma trials.
For the next 5 years:
Publishing consensus guidelines on tracer use and PET imaging response criteria.
Integrating PET tracers into all new SIOPEN trials.
Securing broad access to MFBG and other novel tracers across Europe and beyond.
Building a harmonised imaging and physics infrastructure to support multicentre trials and improve patient outcomes.
Meetings
May 2025 online meeting with members (minutes on website)
Biweekly meeting with chair and co-chair. Topics:
MFBG availability
Contact with Dr. Julian Rogasch-Charite Berlin- and a letter of support for the German MIBG/ MFBG Trial: REDEFINE to be started.
Discussions with Dr. Jakob Stenman on the possibilities of starting a European Trial on Experimental Radionuclide treatment in Children with neuroblastoma in order to support and develop an area that is lacking behind in children compared to adults.
Selected outputs
EANM’20 Virtual - Presentation ID EP-224 : Simplify scoring System vs SIOPEN in prognosis risk assessment in Neuroblastoma. C. Olianti1, M. Allocca2, A. Martini2, A. Tondo3, H. Gauthier4. B91 Paediatric Study.
EANM’20 Virtual - OP 346 : SIOPEN SCORING vs 3 Simplified Scoring Systems in Pediatric Patients with HR-NB-1 and L2-NB. C. Olianti, A. Martini, R. Di Dato, M. Allocca, A. Tondo, H. Gauthier. B91 Paediatric Study.
EANM’20 Virtual - EP-362 - Tandem High-Dose 131I-MIBG Therapy For Paediatric Patients With Relapsed-Refractory High Risk Neuroblastoma: A Dosimetry Based Treatment . C. Altini, M. Villani, B. Cassano, M. Pizzoferro, A. Serra, A. Castellano, V. Cannatà, M. Garganese.
EANM’20 Virtual - A correlation study between clinical outcome and absorbed dose to organs at risk and lesions for patients with High-Risk Neuroblastoma administered with highactivity therapy of 131I-mIBG. B. Cassano, M. Pizzoferro, S. Valeri, S. Donatiello, C. Polito, D. Ciucci, F. Martire A. Castellano, C. Altini, M. C. Garganese V. Cannatà.
EANM’20 Virtual - OP-428 Calibration, radioprotection and dosimetry in Lu-177 treatment of Neuro Endocrine tumours. P. Saletti, S. Raspanti, A. D’Agata, F. Rossi, M. Papi, G. Belli.
EANM’20 Virtual - EPS-040 Gamma Camera Calibration to Perform SPECT/CT-based Dosimetry in 177Lu-DOTATATE Treatments. T. Monserrat Fuertes, N. Montenegro Iglesias, D. Álvarez S104Llorente, M. Peinado Montes, D. San José Olmedo, P. Mínguez.
EANM’20 Virtual - OP-902. Printing 3D Heterogeneous Activity Distributions for Quality Control of SPECT and PET. J. Gear, G. Flux.
EANM’20 Virtual - OP-180. Initial experience with 177lutetium peptide receptor radionuclide therapy for pediatric patients with somatostatin-receptor-positive tumors
M. Pizzoferro, B. Cassano, C. Altini, A. Serra, M. Cefalo, A. Cacchione, M. Villani, A. Castellano, V. Cannatà, M. Garganese.
Interested in joining the Specialty committee?
Please first register to become a SIOPEN member and then contact the specialty committee chair and/or co-chair in order to join the committee.
